• Es befinden sich keine Produkte im Warenkorb.


Literatur und weiterführende Links (Rx 64-69)


Literatur zu Anatomie der Niere (Rx 64)

Brenner and Rector’s The Kidney, 8th ed.

Fritsch H, Leonhardt H, Kühnel W, Spitzer G: Taschenatlas der Anatomie 2. Innere Organe. Thieme, Stuttgart, 2005.

Ichikawa I, Harris RC: Angiotensin actions in the kidney: Renewed insight into the old hormone. Kidney Int 1991; 40:583–589.

Lippert H, Herbold D, Lippert-Burmester W: Anatomie: Text und Atlas, Urban & Fischer bei Elsevier, 2006.

Netter FH: Atlas der Anatomie des Menschen, Thieme, Stuttgart, 2006.

Putz R, Pabst R: Sobotta, Anatomie des Menschen: Allgemeine Anatomie, Bewegungsapparat, Innere Organe, Neuroanatomie.Urban & Fischer bei Elsevier, 2007.

Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989: 320:980–985.

Wein: Campbell-Walsh Urology, 9th ed.


Linksammlung zu Anatomie der Niere (Rx 64)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

Literatur zu Physiologie der Niere (Rx 64)

Besarab A, Bolton WK, Browne JK: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998: 339: 584–592.

Brenner BM: Brenner and Rector’s the Kidney. Saunders, Philadelphia, 2004.

Bushinsky DA: Kidney stones. Adv Intern Med 2001; 47: 219–238.

Dzau VJ: Circulationg versus local renin-angiotensin systems in cardiovascular homeostasis. Circulation 1988; 77: 14–15.

Eknoyan G et al.: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J Med 2002; 347: 2010–2019.

Ersley JA: Erythropoietin. N Engl J Med 1991; 324: 1339–1345.

Hebert SC, Desir G, Giebisch G, Wang W: Molecular diversity and regulation of renal potassium channels. Physiol Rev 2005: 85: 319–371.

Massry SG, Glassock RJ (2001) Textbook of nephrology. Lippincott Williams & Wilkins, Philadelphia.

Mullins LJ, Bailey MA, Mullins JJ: Hypertension, kidney, and transgenics: a fresh perspective. Physiol Rev 2006: 86: 709–746.

Paul M, Poyan-Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006: 86: 747–803.

Vallon V, Muhlbauer, B Osswald H: Adenosine and kidney function. Physiol Rev 2006: 86: 901–940.


Linksammlung zu Physiologie der Niere (Rx 64)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

Literatur zu Diagnostik der Nierenerkrankungen (Rx 65)
Adler SG Fairley K: The Patient with Hematuria, Proteinuria or Both and Abnormal Findings on Urinary Microscopy. In: Schrier RW (Ed) Manual of nephrology. Lippincott Williams& Wilkins, Philadelphia Baltimore New York LondonBuenos Aires Hong Kong Sydney Tokyo, 2000, S. 114–132.

Cockroft DW, Gault MH: Prediction of creatinine-clearance from serum creatinine. Nephron 1976; 16:31–41.

Davison AM, Grunfeld JP: History and clinical examination. In: Cameron S, Davison A, Grunfeld JP, Kerr D and Ritz E (Eds) Oxford Textbook of Nephrology. Chapter 1: Assessment of the patient with renal disease. Oxford University Press, Oxford New York Tokyo, 1992, S. 3–13.

Levey AS, Bosch JP et al:  A more accurate method to estimate glomerular filtration rate from serum creatinine. A new prediction equation. Ann Intern Med 1999; 130:461–470.

Ponticelli C, Mihatsch MJ, Imbascati E: Renal biopsy: performance and interpretation. In: Cameron S, Davison A, Grunfeld JP, Kerr D and Ritz E (Eds) Oxford Textbook of Nephrology. Chapter 1: Assessment of the patient with renal disease. Oxford University Press, Oxford New York, Tokyo, 1992, S. 141–152.

Townsend RR, Older RA: Use of Radiologic Techniques in the Patient with Renal Problems. In: Schrier RW (Ed) Manual of nephrology. Lippincott Williams & Wilkins, Philadelphia, Baltimore New York London Buenos Aires Hong, Kong Sydney Tokyo, 2000, S. 265–297.

Walb D: Diagnostische Masnahmen bei Nierenerkrankungen und Beurteilung der Nierenfunktion. In: Kuhlmann U, Walg C Luft FC (Eds) Nephrologie. Georg Thieme, Stuttgart New York, 1998, S. 1–27.


Linksammlung zu Diagnostik der Nierenerkrankungen (Rx 65)

Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten (Aktualisierung 04/2017, gepl. Überprüfung 2022): https://www.awmf.org/uploads/tx_szleitlinien/043-044l_S3_Harnwegsinfektionen_2017-05.pdf
(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

Webseite für Betroffene der Zystenniere: http://www.pkdcure.de/
(eingesehen am 11.09.2023)

U.S. Organisation: http://www.kdoqi.org
(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

Literatur zu Pathophysiologie, Diagnostik und allgemeine Therapie von HWI (Rx 65)

Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA2002;287:2701-10.

Berger RE. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. J Urol. Sep 2005;174:941-2.

Dwyer PL, O’Reilly M. Recurrent urinary tract infection in the female. Curr Opin Obstet Gynecol. Oct 2002;14:537-43.

Ellis AK, Verma S. Quality of life in women with urinary tract infections: is benign disease a misnomer? J Am Board Fam Pract 2000;13:392-7.

Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003;349:259-66.

Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol. Apr 2005;173:1281-7.

Handley MA, Reingold AL, Shiboski S, Padian NS. Incidence of acute urinary tract infection in young women and use of male condoms with and without nonoxynol-9 spermicides. Epidemiology. 2002;13:431-6.

Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. Aug 15 1996;335:468-74.

Hooton TM, Scholes D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med. Oct 5 2000;343:992-7.

Howes DS, Bogner MP. Urinary tract infections. In: Tintinalli, et al, eds. Emergency Medicine. A Comprehensive Study Guide. 6th ed. New York: McGraw-Hill; 2004:606-612.

Kaiser J, McPherson V, Kaufman L, Huber T. Clinical inquiries. Which UTI therapies are safe and effective during breastfeeding? J Fam Pract. Mar 2007;56:225-8.

Kunin CM: An overview of urinary tract infections. In: Kunin CM (Ed): Urinary Tract Infections: Detection, Prevention and Management, Edition 5. Williams & Wilkins, Baltimore. 1997, S. 4–11

Nicolle LE: A practical guide to the management of complicated urinary tract infection. Drugs 1997; 53:583–594

Stamm WE, Hooton TM: Management of urinary tract infections in adults. New Engl J Med 1993:329:328–333

Talan DA, Stamm We, Reuning-Scherer J, et al. Ciprofloxacin 7-day vs tmp/smx 14-day +/- ceftriaxone for acute uncomplicated pyelonephritis: A randomized double-blind trial. 8th International Congress on Infectious Diseases. 1998.

Weir M, Brien J. Adolescent urinary tract infections. Adolesc Med. Jun 2000;11:293-313.


Linksammlung zu Pathophysiologie, Diagnostik und allgemeine Therapie von HWI (Rx 65)


(eingesehen am 11.09.2023)

Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten (Aktualisierung 04/2017, gepl. Überprüfung 2022): https://www.awmf.org/uploads/tx_szleitlinien/043-044l_S3_Harnwegsinfektionen_2017-05.pdf
(eingesehen am 11.09.2023)


Literatur zu Bakterielle Infektionen: Unterer Harnwegsinfekt (Rx 66)

Cunha B.A.:  Antibiotic selection and control of resistance in the critical care unit.   In: Cunha B.A., ed.  Infectious disease in critical care medicine,  Informa Healthcare New York 2007: 609-624.

Hooton, 2003. Hooton TM: The current management strategies for community-acquired urinary tract infection.  Infect Dis Clin North Am  2003; 17:303-332.

Kahan et al., 2003. Kahan E, Kahan NR, Chinitz DP: Urinary tract infection in women—Physician’s preferences for treatment and adherence to guidelines: A national drug utilization study in a managed care setting.  Eur J Clin Pharmacol  2003; 59:663-668.

Meiland et al., 2002. Meiland R, Geerlings SE, Hoepelman LI: Management of bacterial urinary tract infections in adult patients with diabetes mellitus. Drugs  2002; 62:1859-1868.

Miller and Tang, 2004. Miller LG, Tang AW: Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance.  Mayo Clin Proc  2004; 79:1048-1053.

Nicolle, 2002. Nicolle LE: Urinary tract infection: Traditional pharmacologic therapies.  Am J Med  2002; 113:35S-44S.

Ramakrishnan K, Scheid DC:  Diagnosis and management of acute pyelonephritis in adults.  Am Fam Physician 2005; 71: 933-942.

Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten (Aktualisierung 04/2017, gepl. Überprüfung 2022): https://www.awmf.org/uploads/tx_szleitlinien/043-044l_S3_Harnwegsinfektionen_2017-05.pdf
(eingesehen am 11.09.2023)


Literatur zu Oberer HWI, Pilzinfektionen und Urogenitaltuberkulose (Rx 66)

American Thoracic Society et al, 2005. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America: Controlling tuberculosis in the United States.  Am J Respir Crit Care Med 2005; 172:1169-1227.

Cahill D, Dhanji A, Williams M, et al. Genitourinary tuberculosis in Middle England: look for it or miss it! BJU Int. Feb 2001;87:273-4.

Centers for Disease Control and Prevention and American Thoracic Society, 2003. Centers for Disease Control and Prevention, American Thoracic Society: Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States 2003.  MMWR Morb Mortal Wkly Rep 2003; 52:735-739.

Centers for Disease Control and Prevention, 2005. Centers for Disease Control and Prevention: Guidelines for the investigation of contacts of persons with infectious tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC.  MMWR Morb Mortal Wkly Rep 2005; 54:1-47.

Dye, 2006. Dye C: Global epidemiology of tuberculosis.  Lancet  2006; 367:938-940.

Fisher JF, Newman CL, Sobel JD: Yeast in the urine: Solutions for a budding problem.  Clin Infect Dis 1995; 20:183-189.

Hopewell PC. A clinical view of tuberculosis. Radiol Clin North Am. Jul 1995;33:641-53.

Jung YY, Kim JK, Cho KS. Genitourinary tuberculosis: comprehensive cross-sectional imaging. AJR Am J Roentgenol. Jan 2005;184:143-50.

Kauffman CA, Vazquez JA, Sobel JD, et al: Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases Mycoses Study Group.  Clin Infect Dis 2000; 30:14-18.

Krynytska I, Firket C. Genital tuberculosis in postmenopausal patients. J Obstet Gynaecol. May 2007;27:443-4.

Lenk S, Schroeder J. Genitourinary tuberculosis. Curr Opin Urol. Jan 2001;11:93-8.

Lundstrom T, Sobel J: Nosocomial candiduria: A review.  Clin Infect Dis 2001; 32:1602-1607.

Oravcova E, Lacka J, Drgona L, et al: Funguria in cancer patients: Analysis of risk factors, clinical presentation and outcome in 50 patients.  Infection 1996; 24:319-323.

Phillips JR, Karlowicz MG: Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit.  Pediatr Infect Dis J 1997; 16:190-194.

Ramdial PK, Calonje E, Sydney C, et al. Tuberculids as sentinel lesions of tuberculous epididymo-orchitis. J Cutan Pathol. Nov 2007;34:830-6.

Sharma and Liu, 2006. Sharma SK, Liu JJ: Progress of DOTS in global tuberculosis control.  Lancet 2006; 367:951-952.

Sharma and Mohan, 2006. Sharma SK, Mohan A: Multidrug-resistant tuberculosis: A menace that threatens to destabilize tuberculosis control.  Chest  2006; 130:261-272.

Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Benett JE, Dolin R, edit. Mandell, Douglas and Bennett’s Priciples and practice of infectious diseases. 6. Auflage. Filadelfia: Elsevier; 2005. p. 875-905.

Ward TT, Jones SR. Genitourinary tract infections. In: Betts RF, Chapman SW, Penn RL, edit. Reese and Betts’ A practical approach to infectious diseases. Filadelfia: Lippincott Williams & Wilkins; 2003. p. 493-540.

Warren JW: Catheter-associated urinary tract infections.  Infect Dis Clin North Am 1997; 11:609-622.

Wasserman NF. Inflammatory disease of the ureter. Radiol Clin North Am. 1996;34:1131-56.

Weiss SG 2nd, Kryger JV, Nakada SY, et al: Genitourinary tuberculosis. Urology. 1998;51:1033-4.

World Health Organization, 2003. World Health Organization: Treatment of Tuberculosis: Guidelines for National Programmes, 3rd ed.. Geneva, World Health Organization, 2003.

Linksammlung zu Oberer HWI, Pilzinfektionen und Urogenitaltuberkulose (Rx 66)

RKI-Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2017 unter https://www.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2017.pdf?__blob=publicationFile
(eingesehen am 11.09.2023)

Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten (Aktualisierung 04/2017, gepl. Überprüfung 2022): https://www.awmf.org/uploads/tx_szleitlinien/043-044l_S3_Harnwegsinfektionen_2017-05.pdf
(eingesehen am 11.09.2023)

Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, sehr übersichliche “Leitlinie Brennen beim Wasserlassen”.

Literatur zu Nephro- und Urolithiasis (Rx 67)

Allie-Hamdulay S, Rodgers AL. Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 2005;33:116-24.

Begun FP, Foley WD, Peterson A, White B. Patient evaluation. Laboratory and imaging studies. Urol Clin North Am. Feb 1997;24:97-116.

Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-43.

Borghi L, Meschi T, Amato F, et al. Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. J Urol 1994;152:1095-8.

Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.

Bratslavsky G, Moran ME. Current trends in ureteroscopy. Urol Clin North Am. Feb 2004;31(1):181-7, xi. .

Brown J. Diagnostic and treatment patterns for renal colic in US emergency departments. Int Urol Nephrol 2006;38:87-92.

Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 2002;168: 937-40.

Chaussy C, Eisenberger F, Jocham D, Wilbert DM (1997) Aktuelle Aspekte der extrakorporalen Stoswellenlithotripsie in der Urologie. Deutsches Arzteblatt 94, Heft 47, S. A-3189

Coe FL, Parks JH, Asplin JR (1992): The pathogenesis and treatment of kidney stones. N Entl J Med 327: 1141–1148

Coe FL, Parks JH, Nakagawa Y. Inhibitors and promoters of calcium oxalate crystallization. In: Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. New York, N.Y.: Raven Press, 1992.

Cooper J, Stack G, Cooper T. Intensive medical management of ureteral calculi. Urology 2000;56:575-8.

Cooper JT, Stack GM, Cooper TP. Intensive medical management of ureteral calculi. Urology. Oct 1 2000;56(4):575-8.

Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol 1998;9:1645-52.

De Sio M, Autorino R, Di Lorenzo G, et al. Medical expulsive treatment of distal-ureteral stones using tamsolusin: a single-center experience. J Endourol 2006;20:12-6.

Dellabella M, Milanese G, Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. J Urol 2005;66:712-5.

Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. Dec 2003;170:2202-5.

Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005;174(1):167-72.

Delvecchio FC, Preminger GM. Medical management of stone disease. Curr Opin Urol 2003;13:229-33.

Deutsche Gesellschaft für Ernährung, 1992) Empfehlungen fur die Nahrstoffzufuhr. Frankfurt: Umschau

Fielding JR, Steele G, Fox LA, Heller H, Loughlin KR. Spiral computerized tomography in the evaluation of acute flank pain: a replacement for excretory urography. J Urol 1997;157:2071-3.

Fishbein WN, Carbone PP. Urease catalysis: II. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid. J Biol Chem 1965;240:2407-14.

Gault MH, Chafe LL, Morgan JM, Parfrey PS, Harnett JD, Walsh EA, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine, Baltimore, 1991;70:345-59.

Gerstenbluth RE, Resnick MI. Medical management of calcium oxalate urolithiasis. Med Clin North Am. Mar 2004;88:431-42.

Grady B, Bruce J, Stoller M. Pediatric urolithiasis. J Urol. 1999;161: 200.

Greenstein A, Sofer M, Matzkin H. Efficacy of the Duet lithotripter using two energy sources for stone fragmentation by shockwaves: an in vitro study. J Endourol. Dec 2004;18:942-5.

Griffith DP, Khonsari F, Skurnick JH, James KE. A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol 1988;140:318-24.

Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. Sep 30 2006;368:1171-9.

Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001;59:270-6.

Jackman SV, Potter SR, Regan F, Jarrett TW. Plain abdominal x-ray versus computerized tomography screening: sensitivity for stone localization after nonenhanced spiral computerized tomography. J Urol. Aug 2000;164(2):308-10.

Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: the health professionals’ follow-up study. Kidney Int 2003;64:1022-6.

Kupeli B, Irkilata L, Gurocak S, Tunc L, Kirac M, Karaoglan U, et al. Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy?. Urology. Dec 2004;64(6):1111-5.

Leslie S. Diagnostic evaluation of renal colic in the ED. Emergency Physicians’ Monthly. 2000;7(9):1-9.

Lotan Y, Cadeddu JA, Roerhborn CG, Pak CY, Pearle MS. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol 2004;172(6 pt 1):2275-81.

Loughlin KR, Ker LA. The current management of urolithiasis during pregnancy. Urol Clin North Am. Aug 2002;29:701-4.

Low RK, Stoller ML. Uric acid-related nephrolithiasis. Urol Clin North Am. Feb 1997;24(1):135-48.

Mandel N. Mechanism of stone formation. Semin Nephrol 1996;16:364-74.

Marx J, Hockberger R, Walls R, et al. Rosen’s emergency medicine concepts and clinical practices. Philadelphia: Mosby Inc.; 2006.

Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ. Campbell’s Urology. 9th ed. Philadelphia, Pa: WB Saunders Co; 2002:3229-305.

Moe OW, Abate N, Sakhaee K. Pathophysiology of uric acid nephrolithiasis. Endrocrinol Metab Clin North Am 2002; 31:895-914.

Moe OW. Kidney stones: pathophysiology and medical management. Lancet. Jan 28 2006;367:333-44.

Nambirajan T, Jeschke S, Albqami N, Abukora F, Leeb K, Janetschek G. Role of laparoscopy in management of renal stones: single-center experience and review of literature. J Endourol. Apr 2005;19(3):353-9.

Parivar F, Low RK, Stoller ML: Influence of diet on urinary stones. J Urol 1996; 155: 432–440

Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol 2005;173:848-57.

Pietrow PK, Karellas ME. Medical management of common urinary calculi. Am Fam Physician. Jul 1 2006;74(1):86-94.

Porpiglia F, Destefanis P, Fiori C, et al. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 2000;56:579-82.

Porpiglia F, Destefanis P, Fiori C, Scarpa RM, Fontana D. Role of adjunctive medical therapy with nifedipine and deflazacort after extracorporeal shock wave lithotripsy of ureteral stones. Urology. Jun 2002;59:835-8.

Porpiglia F, Ghignone G, Fiori C, et al. Nifedipine versus tamsulosin for the management of power ureteral stones. J Urol 2004;172:568-71.

Qiang W, Ke Z. Water for preventing urinary calculi. Cochrane Database Syst Rev 2004:CD004292.

Rapp DE, Gerber GS. Management of caliceal diverticula. J Endourol. Nov 2004;18:805-10.

Resnick MI, Pak CY. Urolithiasis. In: A Medical and Surgical Reference. Philadelphia, Pa: WB Saunders Co; 1990.

Ruml LA, Pearle MS, Pak CY. Medical therapy, calcium oxalate urolithiasis. Urol Clin North Am. Feb 1997;24(1):117-33.

Saita A, Bonaccorsi A, Marchese F, et al. Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones. Urol Int 2004;72(Suppl 1):43-5.

Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. Ureteral Stones Clinical Guidelines Panel summary report on the management ofureteral calculi. J Urol 1997;158:1915-21.

Sheir KZ, El-Diasty TA, Ismail AM. Evaluation of a synchronous twin-pulse technique for shock wave lithotripsy: the first prospective clinical study. BJU Int. Feb 2005;95(3):389-93.

Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168:1307-14.

Shekarriz B, Stoller ML. Cystinuria and other noncalcareous calculi. Endocrinol Metab Clin North Am. Dec 2002;31:951-77.

Smith RC, Rosenfield AT, Choe KA, Essenmacher KR, Verga M, Glickman MG, et al. Acute flank pain: comparison of non-contrast-enhanced CT and intravenous urography. Radiology 1995;194:789-94.

Stoller and Bolton, 2000. Stoller MLS, Bolton DM: Urinary stone disease.   In: Tanagho EA, McAninch JW, ed. Smith’s General Urology,  15th ed.. New York: McGraw-Hill; 2000:291-321.

Taylor EN, Curhan GC. Diet and fluid prescription in stone disease. Kidney Int. Sep 2006;70:835-9.

Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-62.

Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004;350:684-93

Tiselius HG. Epidemiology and medical management of stone disease. BJU Int. May 2003;91:758-67.

Tiselius HG. Removal of ureteral stones with extracorporeal shock wave lithotripsy and ureteroscopic procedures. What can we learn from the literature in terms of results and treatment efforts?. Urol Res. Jun 2005;33:185-90.

Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. Jul 1999;162:27-30.

Troxel S, Jones A, Magliola L, et al. Physiologic effect of nefedipine and tamsulosin on contractility of distal ureter. J Endourol 2006;20:565-8.

Webber R, Tolley D, Lingeman J. Kidney stones. Clin Evid. Dec 2005;(14):1048-56.

Williams JC Jr, Kim SC, Zarse CA, McAteer JA, Lingeman JE. Progress in the use of helical CT for imaging urinary calculi. J Endourol. Dec 2004;18(10):937-41.

Wolf JS Jr, Clayman RV. Percutaneous nephrostolithotomy. What is its role in 1997?. Urol Clin North Am. Feb 1997;24(1):43-58.

Yilmaz E, Batislam E, Basar M, et al. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol 2005;173:2010-2.


Linksammlung zu Nephro- und Urolithiasis (Rx 67)

S2k-Leitlinie zur Diagnostik, Therapie und Metaphylaxe der Urolithiasis (AWMF 043-025) Aktualisierung 2018 unter: https://www.awmf.org/uploads/tx_szleitlinien/043-025l_S2k_Diagnostik_Therapie_Metaphylaxe_Urolithiasis_2019-07_1.pdf
(eingesehen am 11.09.2023)


Literatur zu Tubulopathien, tubulointerstitielle Nierenerkrankungen (Rx 68)

Abbate M, Remuzzi G. Proteinuria as a mediator of tubulointerstitial injury. Kidney Blood Press Res. 1999;22:37-46.

Alexopoulos E. Drug-induced acute interstitial nephritis. Ren Fail. 1998;20:809-19.

Aspelin P, Aubry P, Fransson SG et al. Nephrotoxic effects in high-risk patients undergoing angiography (NEPHRIC). N Engl J Med 2003; 348: 491

Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol. Aug 1998;275:246-54.

Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens. Mar 2000;9:133-8.

Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight. J Nephrol. 1998;11:70-5.

Friberg L, Nordberg GF, Vouk VB (Eds) Handbook on the toxicology of metals. Elsevier, Amsterdam, S. 387–442.

Buchet JP, Lauwerys R, Roels H: Renal effects of cadmium body burden of the general population. Lancet 1990; 336: 699–709.

Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E: Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract.2006;104:20–27.

Cox CD, Tsikouris JP Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004;44:327-337.

Cruz DN, Perazella MA. Drug-induced acute tubulointerstitial nephritis: the clinical spectrum. Hosp Pract (Minneap). Feb 15 1998;33:151-2, 157-8, 161-4.

Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int. Dec 1995;48:1912-9.

Gluck SL (1998) Acid-Base. Lancet 352: 474–48.

Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK: Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999;51:521–526.

Hall PW 3d, Dammin GJ. Balkan nephropathy. Nephron. 1978;22:281-300.

Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med. 2006;57:365-80.

Heinrich MC, Kuhlmann MK, Grgic A et al.: Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235: 843.

Huerta C et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45:531–9.

Kleinknecht D. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995;15:228-35.

Kodner CM et al. Diagnosis and management of acute interstitial nephritis. Am Fam Physician. 2003 Jun 15;67:2527–34.

Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 23 2003;348:277-86.

Lin JL, Lin-Tan DT, Yu CC, Li YJ, Huang YY, Li KL. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int. Jun 2006;69:2049-56.

Linton AL, Richmond JM, Clark WF, Lindsay RM, Driedger AA, Lamki LM. Gallium-67 scintigraphy in the diagnosis of acute renal disease. Clin Nephrol. Aug 1985;24:84-7.

Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. Jan 2006;69:213-7.

Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D’Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol. Aug 2000;11(8):1439-48.

Michel DM, Kelly CJ: Acute interstitial nephritis: Immunologic and clinical aspects. J Am Soc Nephrol 1998;9: 506.

Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004;65:1366.

Perazella MA, Eras J:Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937–940.

Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. Jul 1999;56:118-34.

Rose BD (1994) Clinical Physiology of Acid-Base and Electrolyte Disorders. 4th Edition, McGraw-Hill, New York, S. 702–706.

Staessen JA, Lauwerys RR, Bucher JP: Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med 1992; 327: 151–158.

Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. May 31 1999;106:13S-24S.

Zarifian A, Meleg-Smith S, O’donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999; 55:2457-66.


Linksammlung zu Tubulopathien, tubulointerstitielle Nierenerkrankungen (Rx 68)

Weiterführende fachliche Zusammenfassung unter: http://www.merck.com/mmpe/sec17/ch236/ch236c.html und http://emedicine.medscape.com/article/982811-overview
(eingesehen am 11.09.2023)

Selbsthilfe unter https://www.bundesverband-niere.de/ und https://www.dgfn.eu/bundesverband-niere.html 
(eingesehen am 11.09.2023)

Erklärvideos unter https://www.nierenstiftung.de/fuer-betroffene/information/erklaervideos/
(eingesehen am 11.09.2023)

Literatur zu Akutes Nierenversagen (Rx 68)

Better OS, Stein JH (1990) Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322:825.

Conger JD (1995) Interventions in clinical acute renal failure. What are the data? Am J Kidney Dis 1995; 26: 565–580.

Friedrich JO,  Adhikari N, Herridge MS, Beyene J: Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death.  Ann Intern Med  2005; 142:510-524.

Lassnigg A, Schmidlin D, Mouhieddine M, et al: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study.  J Am Soc Nephrol  2004; 15:1597-1605.

Magaldi AJ, Yasuda PN, Kudo LH: Renal involvement in leptospirosis: A pahtophysiologic study. Nephron 1992; 62: 332–339.

Mehta et al., 2002. Mehta RL, Pascual MT, Soroko S, Chertow GM: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA  2002; 288:2547-2553.

Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM SO: TI Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004; 66:1613–1621.

Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial.  JAMA  2004; 291:2328-2334.

Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.  Arch Intern Med  2002; 162:329-336.

Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency.  Am J Kidney Dis  2002; 39:930-936.

Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy.  Kidney Int  2004; 65:1366-1374.Papadimitriou M: Hantavirus nephropathy. Kidney Int 1995; 48: 887–894.

Parker RA, Himmelfarb J, Tolkoff-Rubin N: Prognosis of patients with acute renal failure requiring dialysis: Results of a mutlicenter Sturdy. Am J Kidney Dis1998: 32: 432–438.

Perazella MA, Tray K: Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001 Jul;111(1):64–67.

Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial.  Lancet  2000; 356:26-30.

Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure.  N Engl J Med  2002; 346:305-310.

Seguro AC, Lomar AV, Rocha AS: Acute renal failure of leptospirosis: Nonoliguric and hypokalemic forms. Nephron 1990: 55: 146–152.

Stone GW, McCullough PA, Tumlin JA, et al: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial.  JAMA  2003; 290:2284-2291.

Tepel M, van der Giet M, Schwarzfeld C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.  N Engl J Med  2000; 343:180-184.

Uchino S, Doig GS, Bellomo R, et al: Diuretics and mortality in acute renal failure.  Crit Care Med  2004; 32:1669-1677.

Zager RA: Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996; 49: 314–321.


Linksammlung zu Akutes Nierenversagen (Rx 68)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

(eingesehen am 11.09.2023)

S3-Leitlinie “Versorgung von Patienten mit chronischer nicht-dialysepflichtiger Nierenerkrankung in der Hausarztpraxis”; AWMF 053-048 (Stand 06/2019; Revision geplant 06/2024): Unter https://www.awmf.org/uploads/tx_szleitlinien/053-048l_S3_Versorgung-von-Patienten-mit-nicht-dialysepflichtiger-Niereninsuffizienz__2021-01.pdf
(eingesehen am 11.09.2023)

Selbsthilfe unter https://www.bundesverband-niere.de/ und https://www.dgfn.eu/bundesverband-niere.html
(eingesehen am 11.09.2023)

Erklärvideos unter https://www.nierenstiftung.de/fuer-betroffene/information/erklaervideos/
(eingesehen am 11.09.2023)

Allgemeine Linksammlung zum Thema

Seite der Internisten im Netz über die Niere: http://www.internisten-im-netz.de/de_niere-funktion_829.html
(eingesehen am 11.09.2023)

Universität Fribourg (Schweiz) über die Physiologie der Niere: https://omero-web.unifr.ch/gallery/show_dataset/4355/
(eingesehen am 11.09.2023)

Der Bundesverband Niere e.V. (BN e.V.) ist die Selbsthilfeorganisation der Dialysepatienten und Nierentransplantieren Deutschlands und beschreibt hier die Aufgaben der Niere: http://www.bundesverband-niere.de/bundesverband/die-nieren/funktion-und-aufgaben-der-nieren.html
(eingesehen am 11.09.2023)

Die Deutsche Nierenstiftung informiert die Öffentlichkeit, fördert Forschungen und hilft Betroffenen. Sie ist im Netz unter zu finden unter: http://nierenstiftung.de/. Broschüren zu viele Krankheitsbildern gibt es hier http://nierenstiftung.de/oeffentlichkeitsarbeit/hilfreiche-informationen
(eingesehen am 11.09.2023)


Pharmabrain Logo

European Union Trademark no. 006894216
US Patent and Trademark Office reg. no. 3,705,613
International Registration 1460744
All rights reserved.

Wir sind Pharmabrain.

Pharmabrain GmbH – Wir trainieren Ihren Erfolg
Gesundheitskommunikation, Teamentwicklung, Projektmanagement


Wissenschaftliche Exzellenz, praktische Orientierung, Implementierung


Unsere Enterprise Lösungen



Pharmabrain GmbH
Telefon: +49-30-28091515
E-Mail: support@pharmabrain.org

Research and Training Center

Schumannstr. 7b
D-10117 Berlin


Schumannstr. 7a
D-10117 Berlin